| |
| | Worldwide Biotech: 454 Life Sciences Gets Genome License From Pyrosequencing |
 | | Established in 2000, 454 Life Sciences develops technologies and tools to sequence whole genomes using a massively parallel, scalable platform that compresses the time, cost, sample preparation, and space required to determine the nucleotide sequence of whole genomes. |
 | | This license makes 454 Life Sciences the only company allowed to produce instruments and kits, and provide services that utilize sequencing by synthesis or pyrophosphate based sequencing for whole genome sequencing, such as karyotyping, genotyping and determining sequence-based expression, in the United States, Canada, Europe, Japan, Australia and other countries around the world. |
 | | Under the terms of the agreement, the license gives 454 Life Sciences the exclusive right to use this technology in whole genome analysis, while Pyrosequencing AB will retain the rights to its pyrophosphate- based sequencing technology for all applications not related to whole genome activities. |
| www.findarticles.com /p/articles/mi_m0DHC/is_10_15/ai_107782556 |
|